High-fat overfeeding impairs peripheral glucose metabolism and muscle microvascular eNOS Ser1177 phosphorylation. by Parry, SA et al.
 
Parry, SA, Turner, MC, Woods, RM, James, LJ, Ferguson, RA, Cocks, M, 
Whytock, KL, Strauss, JA, Shepherd, SO, Wagenmakers, AJM, van Hall, G and 
Hulston, CJ
 High-fat overfeeding impairs peripheral glucose metabolism and muscle 
microvascular eNOS Ser1177 phosphorylation.
http://researchonline.ljmu.ac.uk/id/eprint/11375/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Parry, SA, Turner, MC, Woods, RM, James, LJ, Ferguson, RA, Cocks, M, 
Whytock, KL, Strauss, JA, Shepherd, SO, Wagenmakers, AJM, van Hall, G 
and Hulston, CJ (2019) High-fat overfeeding impairs peripheral glucose 





High-fat overfeeding impairs peripheral glucose metabolism and muscle microvascular 1 
eNOS Ser1177 phosphorylation  2 
 3 
Siôn A. Parry1*, Mark C. Turner1,2, Rachel M. Woods1, Lewis J. James1, Richard A. 4 
Ferguson1, Matthew Cocks3, Katie L. Whytock3, Juliette A. Strauss3, Sam O. Shepherd3, 5 
Anton J.M. Wagenmakers3, Gerrit van Hall4,5, Carl J. Hulston1 6 
 7 
1School of Sport, Exercise & Health Sciences, Loughborough University, Loughborough, UK  8 
2University Hospitals of Leicester NHS Trust, Infirmary Square, Leicester, UK  9 
3School of Sport & Exercise Sciences, Liverpool John Moores University, Liverpool, UK  10 
4Clinical Metabolomics Core Facility, Department of Clinical Biochemistry, Rigshospitalet, 11 
Copenhagen, Denmark  12 
5Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark  13 
*Current address: Oxford Centre for Diabetes, Endocrinology and Metabolism, University of 14 
Oxford, Churchill Hospital, Oxford, UK 15 
 16 
ORCiD:  17 
Carl Hulston 18 
0000-0002-5375-1161 19 
 20 
Word count: 4822 21 
Short title: High-fat overfeeding impairs glycemic control 22 
Key words: High-fat diet, glucose kinetics, skeletal muscle, insulin signaling, eNOS 23 
 24 




Address for correspondence 27 
Carl J. Hulston, PhD 28 
School of Sport, Exercise & Health Sciences 29 
Loughborough University 30 
Loughborough 31 
LE11 3TU 32 
Telephone: +44 1509 226 449 33 
Email: c.j.hulston@lboro.ac.uk 34 
 35 
Financial support: The research was funded by the National Institute for Health Research 36 
(NIHR) Leicester Biomedical Research Centre. The views expressed are those of the authors 37 
and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. 38 
 39 














Context: The mechanisms responsible for dietary fat-induced insulin resistance of skeletal 52 
muscle and its microvasculature are only partially understood. 53 
Objective: To determine the impact of high-fat overfeeding on postprandial glucose fluxes, 54 
muscle insulin signaling, and muscle microvascular eNOS content and activation. 55 
Design: Fifteen non-obese volunteers consumed a high-fat (64%) high-energy (+47%) diet for 56 
7 days. Experiments were performed before and after the diet. Stable isotope tracers were used 57 
to determine glucose fluxes in response to carbohydrate plus protein ingestion. Muscle insulin 58 
signaling was determined as well as the content and activation state of muscle microvascular 59 
eNOS.  60 
Results: High-fat overfeeding impaired postprandial glycemic control as demonstrated by 61 
higher concentrations of glucose (+11%; P = 0.004) and insulin (+19%; P = 0.035). 62 
Carbohydrate plus protein ingestion suppressed endogenous glucose production to a similar 63 
extent before and after the diet. Conversely, high-fat overfeeding reduced whole body glucose 64 
clearance (-16%; P = 0.021) and peripheral insulin sensitivity (-26%; P = 0.006). This occurred 65 
despite only minor alterations in skeletal muscle insulin signaling. High-fat overfeeding 66 
reduced eNOS content in terminal arterioles (P = 0.017) and abolished the increase in eNOS 67 
Ser1177 phosphorylation that was seen after carbohydrate plus protein ingestion. 68 
Conclusion: High-fat overfeeding impaired whole-body glycemic control due to reduced 69 
glucose clearance, not elevated endogenous glucose production. The finding that high-fat 70 
overfeeding abolished insulin-mediated eNOS Ser1177 phosphorylation in the terminal 71 
arterioles suggests that impairments in the vasodilatory capacity of the skeletal muscle 72 






Healthy volunteers consumed a high-fat diet for 7 days. The diet impaired peripheral glucose 77 
clearance and abolished insulin-stimulated eNOS phosphorylation within the muscle 78 
























Introduction  101 
Excessive food intake and physical inactivity have driven the obesity epidemic, with obesity 102 
being a major risk factor for the development of insulin resistance and the metabolic syndrome 103 
1. However, just a few days of excessive dietary fat intake can impair insulin action and 104 
glycemic control in healthy non-obese individuals 2-4. Understanding these early responses may 105 
provide insight into metabolic disease progression.  106 
 107 
Impairments in glycemic control may be mediated by the inability of insulin to suppress 108 
endogenous glucose production (EGP) in the liver and/or a reduction in insulin-stimulated 109 
glucose uptake by peripheral tissues 5. The tissue-specific contributions to dietary fat-induced 110 
impairments in glycemic control are only partially understood. One study reported a reduction 111 
in hepatic insulin sensitivity and an increase in basal EGP in healthy men subjected to 5-days 112 
of high-fat overfeeding 6. In that study, high-fat overfeeding had no effect on insulin-stimulated 113 
glucose disposal, suggesting that changes in hepatic glucose metabolism precede that of 114 
peripheral impairments. In contrast, another study reported a reduction in insulin-stimulated 115 
leg glucose uptake after 3-days of high-fat overfeeding, but no change in hepatic insulin 116 
sensitivity or EGP at baseline or following insulin administration 3. Each of these studies 117 
utilized the hyperinsulinemic-euglycemic clamp, which, although useful, can be criticized due 118 
to its failure to mimic postprandial conditions. Under clamp conditions, skeletal muscle is 119 
responsible for 70-80% of glucose disposal, and EGP is completely suppressed. Following 120 
glucose ingestion, splanchnic extraction and skeletal muscle glucose uptake make roughly 121 
equal contributions to meal-derived glucose disposal (~30% each), and EGP is only partially 122 
suppressed (50-60% decrease) 7-10. Thus, the processes governing postprandial glycemic 123 
control are more dynamic/ complex than that of clamps. Moreover, as the normal route for 124 
glucose entry into the body is via the gastrointestinal tract, it is necessary to determine the 125 
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impact of high-fat overfeeding on postprandial glucose fluxes (i.e., meal-derived glucose entry 126 
into the circulation, suppression of EGP, and stimulation of glucose disposal), which can be 127 
achieved through the use of dual-glucose tracers 7,10.  128 
 129 
As well as the classical actions of insulin on the myocyte, recent work has established a possible 130 
role for the skeletal muscle microvasculature in insulin-mediated glucose disposal 11. 131 
Physiological doses of insulin have been shown to increase skeletal muscle perfusion 12-14. 132 
Inhibition of this hemodynamic action by L-NAME (N(ω)-nitro-L-arginine-methyl ester) or L-133 
NMMA (NG-monomethyl-L-arginine acetate) has been shown to reduce skeletal muscle 134 
glucose uptake 15-17. Alternatively, it has been shown that L-NAME administration can impair 135 
glycemic control through inhibition of insulin secretion without changes in peripheral insulin 136 
sensitivity 18, and another study reported that L-NMMA administration prevented vasodilation 137 
during insulin/glucose infusion but did not alter whole body glucose uptake 19. Thus, the role 138 
of the skeletal muscle microvasculature in insulin-mediated glucose disposal requires 139 
clarification. Animal studies suggest that impairments to insulin’s microvascular action could 140 
be a key early event in the development of insulin resistance in response to a high fat diet 20-22. 141 
Importantly, the effect of insulin on the microvasculature is dependent on nitric oxide (NO) 142 
synthesized in the endothelium of terminal arterioles. Terminal arterioles regulate the blood 143 
flow in microvascular units (MVUs), which are the smallest functional elements to adjust 144 
muscle blood flow in response to physiological signals and metabolic demands of the muscle 145 
fibers 23. Each terminal arteriole delivers blood to ± 20 capillaries 23. Increases in insulin 146 
following meal ingestion activate eNOS by means of Ser1177 phosphorylation. This leads to the 147 
production of NO, relaxation of the smooth muscle layer and vasodilation of the terminal 148 
arterioles, thereby increasing blood flow in the MVU's 24. The content of NAD(P)H oxidase in 149 
the endothelial layer of the terminal arterioles may reduce NO bioavailability, and therefore 150 
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microvascular perfusion of the muscle, through NO scavenging by superoxide anions 25,26. 151 
Despite the potential for impaired microvascular perfusion playing a role in lipid-induced 152 
insulin resistance, no studies have investigated the protein content and activation state of eNOS 153 
and NAD(P)H oxidase in response to a high fat diet.    154 
 155 
The present study determined the role of EGP (primarily hepatic), oral glucose appearance, and 156 
whole-body glucose clearance in dysregulation of glycemic control after 7 days of high-fat 157 
overfeeding. To this end, we used stable isotope tracers to assess glucose fluxes in response to 158 
acute oral ingestion of an insulinotropic carbohydrate-protein mixture.  We also determined the 159 
phosphorylation (activation) of key proteins involved in skeletal muscle insulin signaling as 160 
well as the protein content and activation state of eNOS and NADP(H) oxidase. We 161 
hypothesized that high-fat overfeeding would impair glucose clearance, not endogenous 162 
glucose production. We also hypothesized that high-fat overfeeding would impair insulin-163 
stimulated eNOS Ser1177 phosphorylation, thereby identifying the muscle microvasculature as 164 















Fifteen individuals (13 males/ 2 females) age 24 ± 1 y, height 176.1 ± 2.1 cm, body mass 77.15 178 
± 3.07 kg, and body mass index (BMI) 24.8 ± 0.6 kg/m2 participated in this study. Participants 179 
were physically active, non-smokers, with no diagnosis of cardiovascular or metabolic disease, 180 
not taking any medication, and weight stable for ≥ 3 months. The study was approved by the 181 
local ethics committee and every participant provided written informed consent. Experimental 182 
trials were conducted from March 2015 to August 2016. Analysis was completed by May 2018. 183 
The study was registered at ClinicalTrials.gov (identifier: NCT03879187). 184 
 185 
Pre-testing 186 
Participants attended the laboratory for assessment of anthropometric characteristics (height, 187 
body mass and BMI). This information was used to estimate resting energy expenditure (REE) 188 
27. A standard correction for physical activity (1.6 and 1.7 times REE for females and males, 189 
respectively) was applied to estimate total daily energy requirements. This information was 190 
used to determine individual energy intakes for the diet intervention.   191 
 192 
Experimental design 193 
One-week after the pre-testing visit, participants returned to the laboratory to undergo 194 
metabolic testing. Participants then consumed a high-fat, high-energy diet for 7 days. The diet 195 
provided 4749 ± 181 kcal per day, with 188 ± 8 g [16% total energy (TE)] protein, 237 ± 8 g 196 
[20% TE] carbohydrate, and 333 ± 14 g [64% TE] fat intake. All foods were purchased and 197 
prepared by the research team. Participants were instructed to eat everything that was provided, 198 
not to eat any additional food, and to return any uneaten items so that diet values could be 199 
adjusted if necessary. All participants were informed about the importance of strict diet 200 
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adherence. Adherence was checked by daily interviews that were conducted when participants 201 
collected their food bundles. A second metabolic testing session was conducted the morning 202 
after completing the diet. 203 
 204 
Experimental protocol 205 
Participants reported to the laboratory in the morning after an overnight fast (≥ 12 h), having 206 
refrained from strenuous physical activity for ≥ 48 h. After voiding and being weighed, a Teflon 207 
catheter (Venflon; Becton, Dickinson, Plymouth, UK) was inserted into an antecubital vein of 208 
each arm to allow blood sampling and isotope infusion. A baseline blood sample (10 mL) was 209 
obtained before a primed constant infusion of [6,6-2H2]glucose was initiated and continued for 210 
the duration of the experiment. Blood samples were divided between tubes containing EDTA 211 
or a clotting catalyst (Sarstedt, Leicester, UK). Further blood samples were obtained 90, 105 212 
and 120 min into the infusion (referred to as t = -30, -15 and 0 min in results/ figures). Biopsies 213 
were obtained from the vastus lateralis under local anesthesia (Lidocaine 10 mg/mL) using a 214 
5-mm Bergström needle, modified for use with manual suction. Two sections of muscle tissue 215 
were blotted free of blood, snap-frozen in liquid nitrogen, and stored at -80ºC. A third section 216 
of muscle tissue was mounted in Tissue-Tek OCT (Sakura Finetek UK Ltd, Thatcham, UK) 217 
and frozen in liquid nitrogen-cooled isopentane for cryo-sectioning and immunofluorescence 218 
microscopy. Participants then consumed a carbohydrate plus protein solution. Further blood 219 
samples were obtained at 15, 30, 45, 60, 90- and 120-min post-ingestion, and additional muscle 220 
biopsies were obtained at 30- and 120-min post-ingestion.  221 
 222 
Two participants did not undergo the muscle biopsy procedure, so measurements of skeletal 223 
muscle insulin signaling are reported for n = 13. Data for immunofluorescence microscopy are 224 
reported for n = 12 and data for muscle glycogen are reported for n = 11 due to tissue quantity 225 
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limitations. Data for glucose kinetics are reported for n = 14 due to a technical issue with the 226 
preparation of isotopes for one of the trials. All other data reported for n = 15.    227 
 228 
Carbohydrate plus protein beverage 229 
The test beverage was a 12.5% glucose solution (48.4 g glucose plus 1.6 g [U-13C]glucose in 230 
400 mL of water) with 15 g whey protein (UltraWhey 90; Volac, Hertfordshire, UK). Whey 231 
protein was added to the solution as most meals will contain protein and to increase the 232 
insulinotropic effect of the beverage.  233 
 234 
Blood analyses 235 
Plasma samples were analyzed for triacylglycerol (TAG), total cholesterol, high-density 236 
lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) (Horiba Medical, 237 
Northampton, UK) and non-esterified fatty acids (NEFA; Randox, County Antrim, UK) using 238 
a semi-automated analyzer (Pentra 400; Horiba Medical, Northampton, UK). Serum insulin 239 
was determined using ELISA (EIA-2935; DRG instruments GmBH, Marburg, Germany). 240 
Plasma glucose concentration and enrichment was determined using liquid chromatography-241 
tandem mass spectrometry (LC-MS/MS) as previously described 28.   242 
 243 
Muscle analyses 244 
Glycogen analysis 245 
Glycogen content was determined as glycosyl units after acid hydrolysis and was measured 246 
spectrophotometrically. The coefficient of variation for glycogen determination was 7-11% 247 
(determined on multiple preparations from 3 separate biopsies).      248 
 249 
Western blotting  250 
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To investigate skeletal muscle insulin signaling, commercially available antibodies were used 251 
to determine the phosphorylation of key proteins (Akt Ser473 [Cell Signaling #4060], Akt Thr308 252 
[Cell Signaling #13038], AS160 Ser588 [Cell Signaling #8730], and AS160 Thr642 [Cell 253 
Signaling #8881] by SDS-PAGE and Western blotting as previously described 29 254 
 255 
Quantitative immunofluorescence 256 
Details of the specific quantification techniques can be found below, and all techniques have 257 
been described in detail previously, including antibody specificity experiments 30,31. All 258 
techniques used frozen muscle biopsy samples cryosectioned to a thickness of 5 µm, mounted 259 
onto uncoated glass microscope slides so that transverse orientated samples could be used for 260 
analysis. Two sections from each condition (pre and post high-fat overfeeding; 0 and 30 min) 261 
within a participant were placed on the same slide and analysis was performed in duplicate 262 
(two slides).  263 
 264 
Sections were fixed in acetone and ethanol (3:1). For assessment of eNOS Ser1177/eNOS ratio, 265 
sections were triple stained with antibodies against eNOS (Transduction Laboratories, 266 
Lexington, KY, USA), eNOS Ser1177 (Cell Signaling Technology, Beverly, MA, USA) and 267 
anti-α smooth muscle actin (αSMA; Abcam, Cambridge, UK). For assessment of NOX2 and 268 
p47phox content, sections were double stained with either NOX2 or p47phox (kind gift from 269 
Prof Mark Quinn, Montana State University) and anti-αSMA. All sections were then incubated 270 
with appropriate secondary antibodies (Invitrogen, Paisley, UK) in combination with the 271 
endothelial marker Ulex Europaeus-FITC conjugated (UEA-I-FITC; Sigma-Aldrich, UK).  272 
 273 
Images were acquired using an inverted confocal microscope (Zeiss LSM-710, Carl Zeiss, 274 
Germany) with a 40x NA oil immersion objective. Alexa Fluor 405 was excited using the 405 275 
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nm line of the diode laser and detected with 371-422 nm emission. FITC fluorescence was 276 
excited with a 488 nm line of the argon laser and detected with 493–559 nm emission. Alexa 277 
Fluor 546 and 633 fluorophores were excited with 543 nm and 633 nm lines of the helium–278 
neon laser and 548–623 nm and 638–747 nm emission, respectively. Identical settings were 279 
used for all image capture within each participant.  280 
 281 
All image analysis was performed using ImagePro Plus 5.1 (Media Cybernetics Inc, Bethesda, 282 
MD, USA). Blood vessels were divided into either capillaries or arterioles using the αSMA 283 
image. The endothelial (UEA-I-FITC) outline was then overlaid onto the corresponding 284 
vascular enzyme image. Mean fluorescence intensity of the vascular enzyme signal was then 285 
quantified within the endothelial specific area. Diameter of the arterioles was determined on 286 
calibrated images. Vessels larger than 20 µm in diameter were excluded to remove 3rd and 4th 287 
order arterioles 32 from the analysis. As eNOS and eNOS Ser1177 phosphorylation had been 288 
stained on the same sections it was possible to establish eNOS Ser1177/eNOS ratio on an 289 
individual vessel basis, as the same endothelial outline could be placed over both eNOS and 290 
eNOS Ser1177 images. The researcher was blinded to condition during imaging and analysis, 291 
and all analysis was conducted by the same researcher. 6 ± 1 arterioles and 139 ± 11 capillaries 292 
were assessed per participant for eNOS content and eNOS Ser1177 phosphorylation. 8 ± 1 293 
arterioles and 148 ± 11 capillaries were assessed per participant for NOX2 content. 8 ± 1 294 
arterioles and 154 ± 14 capillaries were assessed per participant for p47phox content. 295 
 296 
Calculations 297 
Tracer calculations were performed using a non-steady state, single-pool model as previously 298 
described 33. Peripheral insulin sensitivity was calculated as the mean glucose clearance rate 299 
during the 2 h postprandial period divided by the mean serum insulin concentration over the 300 
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same period 34,35. Homeostatic model assessment of insulin resistance (HOMA-IR) was 301 
calculated as described by 36. Area under the curve (AUC) was calculated using the trapezoidal 302 
rule with zero as the baseline.  303 
 304 
Statistics 305 
All data are presented as means ± standard error of the mean (SEM). A Shapiro-Wilk test was 306 
performed to test for normal distribution. Statistical analysis was performed using SPSS v23 307 
for windows. Paired t-tests were used to make pre to post high-fat overfeeding comparisons 308 
where appropriate. All remaining data were compared using a two-way (trial x time) RM 309 
ANOVA, followed with Bonferroni-adjusted post-hoc t-tests where appropriate. Statistical 310 

















Results  326 
Body mass and fasting blood parameters 327 
The effect of high-fat overfeeding on body mass and fasting blood parameters is shown in 328 
Table 1. High-fat overfeeding increased body mass, plasma glucose, serum insulin, HOMA-329 
IR, total cholesterol and HDL cholesterol. LDL cholesterol was unaffected by the diet, whereas 330 
TAG and NEFA decreased.   331 
 332 
Postprandial plasma glucose and serum insulin  333 
Plasma glucose and serum insulin increased in response to carbohydrate plus protein ingestion, 334 
peaking at 30-45 min (Figure 1A and 1B, respectively). There was a main effect of trial (P = 335 
0.004) and a trial x time interaction (P = 0.012) for plasma glucose (Figure 1A), with plasma 336 
glucose at 30- and 45-min time points being higher after high-fat overfeeding than before. 337 
Postprandial plasma glucose AUC (0 – 120 min) increased by 11% after high-fat overfeeding 338 
(596 ± 23 mmol/L per 120 min before vs. 663 ± 19 mmol/L per 120 min after; P = 0.004). A 339 
main effect of trial (P = 0.034) and a trial x time interaction (P = 0.009) were also evident for 340 
serum insulin (Figure 1B), with serum insulin at the 45-min time point being higher after high-341 
fat overfeeding than before. Postprandial serum insulin AUC increased by 19% after high-fat 342 
overfeeding (34,164 ± 4,525 pmol/L per 120 min before vs. 40,715 ± 3,143 pmol/L per 120 343 
min after; P = 0.035).  344 
 345 
EGP, oral glucose appearance, and whole-body glucose clearance 346 
There was a trial x time interaction for EGP (P = 0.009; Figure 2A). High-fat overfeeding 347 
reduced EGP during fasting and early postprandial measurements, and carbohydrate plus 348 
protein ingestion suppressed EGP to a similar extent before and after high-fat overfeeding. 349 
Thus, alterations in EGP did not contribute to elevated glucose concentrations. Oral glucose 350 
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appearance was unaffected by high-fat overfeeding, although there was a tendency for a trial x 351 
time interaction (P = 0.062; Figure 2B). Lastly, there was a main effect of trial (P = 0.025) for 352 
whole body glucose clearance, with high-fat overfeeding resulting in reduced glucose clearance 353 
rate (Figure 2C). When calculated for the entire 2 h oral glucose challenge, high-fat overfeeding 354 
reduced time-averaged whole-body glucose clearance rate by 16% (3.2 ± 0.2 mL/kg/min post 355 
vs. 3.8 ± 0.2 mL/kg/min pre; P = 0.021). Thus, elevated glucose concentrations observed after 356 
high-fat overfeeding were due to reduced glucose disposal and not increased liver glucose 357 
output.  358 
 359 
Peripheral insulin sensitivity 360 
Peripheral insulin sensitivity decreased by 26% after high-fat overfeeding (10.4 ± 1.7 361 
mL/kg/min/nmol/L post vs. 14.2 ± 1.6 mL/kg/min/nmol/L pre; P = 0.006).  362 
 363 
Skeletal muscle insulin signaling  364 
The phosphorylation of key intermediates of the insulin signaling cascade is shown in Figure 365 
3. Phosphorylation of Akt Ser473, Akt Thr308, AS160 Ser588 and AS160 Thr642 increased from 366 
0 to 30 min after carbohydrate plus protein ingestion (P < 0.05). This response was not affected 367 
by high-fat overfeeding. Phosphorylation of Akt Ser473, Akt Thr308 and AS160 Thr642 decreased 368 
from 30 to 120 min. However, phosphorylation of AS160 Thr642 was higher at 120 min than at 369 
0 min. There was a trial x time interaction for AS160 Ser588 (P = 0.042). Before high-fat 370 
overfeeding, phosphorylation of AS160 Ser588 remained elevated 120 min after carbohydrate 371 
plus protein ingestion. After high-fat overfeeding, phosphorylation of AS160 Ser588 returned 372 
to baseline at 120 min.  373 
 374 
Muscle glycogen 375 
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High-fat overfeeding had no effect on muscle glycogen content. Fasting muscle glycogen 376 
content was 430 ± 37 mmol/kg dm before high-fat overfeeding and 398 ± 28 mmol/kg dm after. 377 
Carbohydrate plus protein ingestion did not affect muscle glycogen content either, such that 378 
values at 120 min were comparable to those seen at 0 min. 379 
 380 
Total and phosphorylated eNOS 381 
eNOS content of terminal arterioles and capillaries is shown in Figure 4. High-fat overfeeding 382 
reduced eNOS content within terminal arterioles by 6% (P = 0.017), whereas high-fat 383 
overfeeding did not affect eNOS content within the capillaries (p = 0.197).  High-fat 384 
overfeeding also altered eNOS phosphorylation (Figure 5). Before high-fat overfeeding, 385 
carbohydrate plus protein ingestion increased eNOS Ser1177 phosphorylation within terminal 386 
arterioles by 11%. This effect was no longer present after high-fat overfeeding (Figure 5C; trial 387 
x time interaction, P = 0.007). A near identical response was observed when eNOS Ser1177 388 
phosphorylation was normalized to eNOS content, with nutrient intake resulting in an 8% 389 
increase in eNOS Ser1177/eNOS before high-fat overfeeding but no increase after (Figure 5D; 390 
trial x time interaction, P = 0.039). A similar response was observed within the capillaries, with 391 
a nutrient-stimulated 7% increase in eNOS Ser1177/eNOS before high-fat overfeeding but no 392 
increase after (Figure 5D; trial x time interaction, P = 0.013).   393 
 394 
NAD(P)H oxidase 395 
The protein content of the NAD(P)H oxidase subunits NOX2 (enzymatic subunit) and p47phox 396 
(main regulator subunit) was determined within terminal arterioles and capillaries. High-fat 397 
overfeeding had no effect on the content of either subunit of the NAD(P)H oxidase complex 398 





The tissue-specific changes in glucose metabolism that underpin dietary fat-induced 402 
impairments in glycemic control are not fully understood. The main observation of this study 403 
was that 7 days of high-fat overfeeding led to an increase in postprandial glucose concentration 404 
that was attributable to a reduction in whole body glucose clearance, not elevated EGP. This 405 
suggests that peripheral tissue (such as skeletal muscle) is the primary site of early lipid-406 
induced impairments in glucose metabolism. Despite this, we observed little to no change in 407 
skeletal muscle insulin signaling, suggesting that mechanisms other than impaired insulin 408 
signaling are responsible for the reduction in glucose clearance. Notably, high-fat overfeeding 409 
abolished insulin-mediated eNOS Ser1177 phosphorylation in skeletal muscle terminal 410 
arterioles, suggesting that reduced NO production leading to reduced perfusion of skeletal 411 
muscle in response to insulin may be involved in mediating impaired glucose clearance in 412 
response to 7 days of high-fat overfeeding.  413 
 414 
High-fat overfeeding has frequently been applied in animal studies aiming to better understand 415 
the mechanisms leading to obesity and insulin resistance. These studies are consistent in 416 
suggesting that hepatic insulin resistance precedes that of skeletal muscle insulin resistance 37-417 
40. Human research has produced equivocal findings, with both the liver 6 and skeletal muscle 418 
3 suggested as the primary site of altered glucose metabolism. Brons et al. 6 reported a 26% 419 
increase in basal EGP after high-fat overfeeding that resulted in a 0.46 mmol/L increase in 420 
fasting glucose. In contrast, we observed a 7% decrease in basal EGP despite a significant 421 
increase in fasting plasma glucose. The reason for this discrepancy is unclear, as both the 422 
subject characteristics and the diet intervention were similar between the two studies. 423 
Balancing EGP with exogenous glucose supply is an essential component of glycemic control, 424 
and one that is impaired in type 2 diabetes 41. We found that the ability to suppress EGP in 425 
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response to carbohydrate plus protein ingestion was adequately maintained following high-fat 426 
overfeeding. It is not possible to consider this observation in the context of the data from Brons 427 
et al. 6 as their use of a hyperinsulinemic-euglycemic clamp led to the complete suppression of 428 
EGP, regardless of diet. However, individuals with prediabetes also retain adequate 429 
suppression of EGP despite postprandial hyperglycemia relative to individuals with normal 430 
glucose tolerance 42. Thus, in the early stages of insulin resistance it seems that alterations in 431 
hepatic glucose metabolism do not contribute to whole body impairments in glycemic control. 432 
We also determined oral glucose appearance rate and found that it was not affected by 7 days 433 
of high-fat overfeeding. The proportion of ingested glucose reaching the systemic circulation 434 
after 2 h was 57% before high-fat overfeeding and 53% after, which is comparable to that 435 
reported for healthy individuals 10.  436 
 437 
High-fat overfeeding caused a 16% decrease in whole body glucose clearance, which is in close 438 
agreement with the 20% decrease in leg glucose uptake recently reported after 3 days of 439 
increased fat intake 3. This is also comparable to the physiology of prediabetes, where 440 
postprandial hyperglycemia has been attributed to reduced glucose clearance, not increased 441 
oral glucose appearance or increased EGP 42. Skeletal muscle is a major contributor to insulin-442 
stimulated glucose disposal both under clamp conditions 43 and following glucose ingestion 7-443 
10. We therefore determined the effect of high-fat overfeeding on components of the skeletal 444 
muscle insulin signaling cascade. We focused our attention on Akt and the 160-kDa Akt 445 
substrate (AS160; also known as TBC1D4); the latter has been identified as the most proximal 446 
component of the insulin-signaling cascade linked to GLUT4 translocation 44-46 and an 447 
important regulator of insulin-stimulated skeletal muscle glucose uptake 47. As insulin-448 
stimulated AS160 activation is impaired in skeletal muscle of type 2 diabetics 48, this protein 449 
could play a role in dietary lipid-induced impairments in muscle glucose uptake. In the present 450 
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study, carbohydrate plus protein intake led to a robust increase in the phosphorylation of Akt 451 
Ser473 and Thr308 as well as AS160 Ser588 and Thr642. However, high-fat overfeeding had little 452 
to no effect on basal or carbohydrate plus protein-stimulated phosphorylation of either protein. 453 
Others have reported similar. For example, acute lipid-heparin infusion was found to decrease 454 
glucose disposal by 50%, without changes in Akt Ser473 phosphorylation 49, and high-fat 455 
overfeeding reduced insulin-stimulated leg glucose uptake independent of changes in Akt 456 
Thr308 or AS160 PAS phosphorylation 3. Collectively, these findings suggest that alterations in 457 
Akt/AS160 activation do not play a role in early lipid-induced impairments in glucose disposal, 458 
at least in response to high fat food intake for up to 7 days.   459 
 460 
In the study by Lundsgaard et al. 3, reduced leg glucose uptake was attributed to increased 461 
PDH-E1α Ser300 phosphorylation and a downregulation in oxidative glucose disposal. Insulin-462 
induced GLUT4 translocation in combination with activation of PDH plays a key role in 463 
determining insulin-stimulated glucose oxidation 50, which is an important route of glucose 464 
disposal 51. It is well known that high-fat feeding inhibits PDH and reduces carbohydrate 465 
oxidation both at rest and during exercise 52,53. Thus, whilst we do not have data on PDH 466 
activity or whole-body carbohydrate oxidation, it is likely that high-fat overfeeding inhibited 467 
PDH and reduced oxidative glucose disposal, which could partially explain the reduction in 468 
glucose clearance. Glucose taken up by skeletal muscle can also be diverted to glycogen 469 
storage. In the present study, basal muscle glycogen was unaffected by high-fat overfeeding, 470 
suggesting that the amount of carbohydrate provided was enough to maintain glycogen 471 
synthesis rates in the high fat feeding period. Additionally, acute carbohydrate plus protein 472 
ingestion did not stimulate glycogen synthesis either before or after high-fat overfeeding, 473 
supporting the idea that ingested carbohydrate may have been partitioned towards oxidative 474 




High-fat overfeeding caused a small but significant 6% reduction in eNOS content in terminal 477 
arterioles. Perhaps more importantly, high-fat overfeeding abolished the increase in eNOS 478 
Ser1177 phosphorylation that was seen after carbohydrate plus protein ingestion. 479 
Phosphorylation of eNOS at Ser1177 is essential to insulin-mediated-NO production by 480 
endothelial cells 54. Given that increases in insulin-mediated skeletal muscle perfusion are NO 481 
dependent 15, impaired eNOS Ser1177 phosphorylation may contribute to reduced glucose 482 
clearance following increased fat intake. Mechanistic support for the role of eNOS 483 
phosphorylation in enhancing skeletal muscle perfusion and glucose uptake comes from 484 
Kubota and colleagues 55. In a series of elegant experiments, these authors demonstrated that 485 
impairments in insulin-mediated eNOS phosphorylation led to reduced skeletal muscle 486 
perfusion and impaired skeletal muscle glucose uptake. Moreover, restoration of insulin-487 
mediated eNOS phosphorylation completely restored skeletal muscle perfusion and glucose 488 
uptake in mice lacking endothelial IRS-2 and those fed a high fat diet 55. The possibility that 489 
impairments in insulin’s microvascular action may be an early event in the development of 490 
lipid-induced insulin resistance is supported by recent animal work. Premilovac et al. 22 491 
increased fat intake from 4.8% to 9.0% in Sprague Dawley rats and demonstrated that lipid-492 
induced impairments in insulin-stimulated muscle glucose uptake originated solely from 493 
impairments in insulin’s microvascular actions. In that study 22, the insulin sensitivity of the 494 
muscle fibers remained intact, which is in line with our observations in the present study. In 495 
contrast, animals fed a 22% fat diet experienced insulin resistance in both the microvasculature 496 
and the muscle fibers 22. Unlike the impairment in the insulin-induced activation of eNOS, 497 
high-fat overfeeding did not change the protein content of endothelial specific NOX2 498 
(enzymatic subunit) and of p47phox (main regulator subunit) of NAD(P)H oxidase in skeletal 499 
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muscle terminal arterioles and capillaries, suggesting that 7 days of high-fat overfeeding does 500 
not increase superoxide anion production by NAD(P)H oxidase.  501 
 502 
As discussed above, the finding that 7 days of high-fat overfeeding impaired insulin-mediated 503 
eNOS phosphorylation in terminal arterioles could mean that a reduced ability to increase 504 
muscle perfusion in response to carbohydrate plus protein ingestion was responsible for 505 
reduced glucose clearance. However, we cannot be certain of this as we do not have a measure 506 
of muscle perfusion. It is also difficult to demonstrate causality in human experiments, and thus 507 
any observation of reduced muscle perfusion alongside impaired glucose clearance could be 508 
an epiphenomenon. Thus, further work is required to confirm whether dietary lipid-induced 509 
impairments in eNOS phosphorylation contribute to reduced glucose clearance. A further 510 
limitation of the present study is the lack of a control group maintaining their habitual diet. 511 
However, we had to consider the ethical correctness of including a separate control group that 512 
would undergo numerous muscle biopsies. For this reason, we chose to compare our 513 
experimental diet against our participant’s habitual food intake, as we have done previously 4.     514 
 515 
In conclusion, 7 days of high-fat overfeeding impaired whole-body glycemic control in healthy 516 
non-obese individuals. This was due to reduced glucose clearance, not elevated EGP. The 517 
reduction in glucose clearance occurred without an impairment in skeletal muscle insulin 518 
signaling, suggesting that an alternative mechanism is responsible for this effect of the high-519 
fat diet. This study is the first to show that the insulin-induced Ser1177 phosphorylation of eNOS, 520 
which is known to lead to vasodilation of terminal arterioles after mixed meal ingestion, is 521 
impaired after 7 days of high-fat overfeeding. An additional strength of this study is the use of 522 
a carbohydrate-protein mixture to simultaneously create hyperglycemia and hyperinsulinemia, 523 
22 
 
which is more physiologically relevant than the clamp techniques that have been used in 524 
previous studies.   525 
 526 
Data availability 527 
The datasets generated during the current study are not publicly available but are available from 528 
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Table and figure legends  741 
Table 1. NEFA, non-esterified fatty acids; TAG, triacylglycerol; HDL, high-density 742 
lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; HOMA-IR, homeostatic 743 
model assessment of insulin resistance. Data presented are means ± SEM (n = 15).  744 
 745 
Figure 1. Plasma glucose (A) and serum insulin (B) before (pre) and after (post) 7 days of high-746 
fat overfeeding. Time points -30 – 0 min represent the final 30 min of the 2-h pre-infusion 747 
period. All subsequent time points are following the ingestion of carbohydrate plus protein 748 
(indicated by dotted line). Data presented are means ± SEM (n = 15). *significantly different 749 
between trials at the annotated time point (P < 0.05).  750 
 751 
Figure 2. Endogenous glucose production (EGP) (A), oral glucose appearance (B), and whole-752 
body glucose clearance rate (C) before (pre) and after (post) 7 days of high-fat overfeeding. 753 
Time points -30 – 0 min represent the final 30 min of the initial 2-h pre-infusion period. All 754 
subsequent time points are following ingestion of carbohydrate plus protein (indicated by 755 
dotted line). Data presented are means ± SEM (n = 14).  756 
 757 
Figure 3. Phosphorylation of skeletal muscle Akt Ser473 (A), Akt Thr308 (B), AS160 Ser588 (C), 758 
and AS160 Thr642 (D) during fasting and following ingestion of carbohydrate plus protein, 759 
before (pre) and after (post) 7 days of high-fat overfeeding. Data presented are means ± SEM 760 
(n = 13). AU, arbitrary units. †significantly higher than 0 min (P < 0.05). ‡significantly lower 761 
than 30 min (P < 0.05).    762 
 763 
Figure 4. eNOS content in terminal arterioles and capillaries before (pre) and after (post) 7 days 764 
of high-fat overfeeding. A, representative confocal microscopy images of skeletal muscle 765 
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arterioles from pre- (a) and post-high-fat overfeeding (b). The skeletal muscle microvascular 766 
endothelium was revealed using Ulex europaeus-FITC conjugated lectin (UEA-I) (green). 767 
Skeletal muscle eNOS expression was revealed using Alexa Fluor 546 conjugated secondary 768 
antibody (red). Images not shown, arterioles and capillaries were differentiated using anti-α 769 
smooth muscle actin in combination with Alexa Fluor 405 conjugated secondary antibody. Bar 770 
represents 10 μm. B, mean fluorescence intensity of eNOS is summarized. Data presented as 771 
means ± SEM (n = 12). *Significantly lower than before high-fat overfeeding (P < 0.05).  772 
 773 
Figure 5. eNOS phosphorylation in terminal arterioles and capillaries during fasting (0 min) 774 
and 30 min after consuming carbohydrate plus protein, before (pre) and after (post) 7 days of 775 
high-fat overfeeding. A and B, representative confocal microscopy images of skeletal muscle 776 
arterioles from pre- (A) and post-high-fat overfeeding (B), in the fasted (a) and stimulated (b) 777 
state. The skeletal muscle microvascular endothelium was revealed using Ulex europaeus-778 
FITC conjugated lectin (UEA-I) (green). Skeletal muscle eNOS Ser1177 phosphorylation was 779 
revealed using Alexa Fluor 633 conjugated secondary antibody (red). Images not shown, 780 
arterioles and capillaries were differentiated using anti-α smooth muscle actin in combination 781 
with Alexa Fluor 405 conjugated secondary antibody. Bar represents 10 μm. C, mean 782 
fluorescence intensity of eNOS Ser1177 is summarized. D, eNOS Ser1177 phosphorylation 783 
normalized to eNOS content. Data presented as means ± SEM (n = 12). †Significant increase 784 
from 0 min (fasted) (P < 0.05).  785 
 786 
Figure 6. NOX2 and p47phox content in terminal arterioles and capillaries before (pre) and 787 
after (post) 7 days of high-fat overfeeding. A and B, representative confocal microscopy images 788 
of skeletal muscle from pre- (a) and post-high-fat overfeeding (b), illustrating NOX2 (A) and 789 
p47phox (B). The skeletal muscle microvascular endothelium was revealed using Ulex 790 
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europaeus-FITC conjugated lectin (UEA-I) (green). Skeletal muscle NOX2 and p47phox 791 
expression were revealed using an Alexa Fluor 546 conjugated secondary antibody (red). 792 
Images not shown, arterioles and capillaries were differentiated using anti-α smooth muscle 793 
actin in combination with Alexa Fluor 405 conjugated secondary antibody. Bar represents 25 794 
μm. C, mean fluorescence intensity of NOX2 is summarized. D, mean fluorescence intensity 795 
of p47phox is summarized. Data presented as means ± SEM (n = 12).  796 
